Analyst consensus rating
Inhibikase Therapeutics Analyst Rating: Strong Buy
Direct answer
Inhibikase Therapeutics's consensus rating is Strong Buy.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $5.55.
Forecast evidence checked November 21, 2026.
Get free Inhibikase Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.32
- Average price target
- $5.55
- High price target
- $8.00
- Low price target
- $1.50
- Low target gap
- +13.6%
- Target upside
- +320.5%
- High target gap
- +506.1%
- Target range width
- 492.4%
- Consensus rating
- Strong Buy
- Analysts
- 10
- Evidence date
- November 21, 2026
- Valid through
- November 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Inhibikase Therapeutics?
Inhibikase Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $5.55.
How far are Inhibikase Therapeutics's low and high targets from the recorded price?
The low target implies +13.6%, while the high target implies +506.1%.
How many analysts are included in Inhibikase Therapeutics's consensus?
The verified consensus includes 10 analysts.
How is Inhibikase Therapeutics's target upside or downside calculated?
The average target of $5.55 is divided by the recorded price of $1.32, then one is subtracted to produce +320.5%. This does not guarantee a future return.
When was Inhibikase Therapeutics's analyst forecast verified?
The data was verified on 2026-11-21. The dataset is valid through 2026-11-28.